John L Magnani
Overview
Explore the profile of John L Magnani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peterson J, Smith T, Rock E, Magnani J
Cureus
. 2024 Jul;
16(6):e61996.
PMID: 38983984
Selectins are cell adhesion proteins discovered in the 1980s. As C-type lectins, selectins contain an essential calcium ion in the ligand-binding pocket and recognize the isomeric tetrasaccharides sialyl Lewis (sLe)...
2.
Enjeti A, Fogler W, Smith T, Lincz L, Bond D, Magnani J
Br J Haematol
. 2024 Apr;
204(6):2264-2274.
PMID: 38659295
The interaction of acute myeloid leukaemic (AML) blasts with the bone marrow (BM) microenvironment is a major determinant governing disease progression and resistance to treatment. The constitutive expression of E-selectin...
3.
Uy G, DeAngelo D, Lozier J, Fisher D, Jonas B, Magnani J, et al.
Blood Rev
. 2024 Mar;
65:101184.
PMID: 38493006
E-selectin, a cytoadhesive glycoprotein, is expressed on venular endothelial cells and mediates leukocyte localization to inflamed endothelium, the first step in inflammatory cell extravasation into tissue. Constitutive marrow endothelial E-selectin...
4.
Jia Y, Zhang W, Basyal M, Chang K, Ostermann L, Burks J, et al.
Leukemia
. 2023 Apr;
37(6):1379-1383.
PMID: 37085610
No abstract available.
5.
Maksimos M, Muz B, Magnani J, Azab A
Blood Cancer J
. 2023 Apr;
13(1):48.
PMID: 37029121
No abstract available.
6.
Dampier C, Telen M, Wun T, Brown R, Desai P, El Rassi F, et al.
Blood
. 2022 Aug;
141(2):168-179.
PMID: 35981565
The efficacy and safety of rivipansel, a predominantly E-selectin antagonist, were studied in a phase 3, randomized, controlled trial for vaso-occlusive crisis (VOC) requiring hospitalization (RESET). A total of 345...
7.
DeAngelo D, Jonas B, Liesveld J, Bixby D, Advani A, Marlton P, et al.
Blood
. 2021 Sep;
139(8):1135-1146.
PMID: 34543383
Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A...
8.
Morikis V, Hernandez A, Magnani J, Sperandio M, Simon S
Front Immunol
. 2021 May;
12:663886.
PMID: 33995392
Neutrophils are essential to protect the host against invading pathogens but can promote disease progression in sickle cell disease (SCD) by becoming adherent to inflamed microvascular networks in peripheral tissue...
9.
Myers Jr D, Ning J, Lester P, Adili R, Hawley A, Durham L, et al.
J Vasc Surg Venous Lymphat Disord
. 2021 Apr;
10(1):211-220.
PMID: 33872819
Background: This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation...
10.
Barbier V, Erbani J, Fiveash C, Davies J, Tay J, Tallack M, et al.
Nat Commun
. 2020 Apr;
11(1):2042.
PMID: 32341362
The endothelial cell adhesion molecule E-selectin is a key component of the bone marrow hematopoietic stem cell (HSC) vascular niche regulating balance between HSC self-renewal and commitment. We now report...